Tirzepatide Genopharm 30 mg

Tirzepatide is a dual GIP/GLP-1 receptor agonist that combines the action of two incretin hormones in a single peptide. By stimulating insulin secretion after meals and suppressing glucagon secretion between meals, it supports both post-meal and fasting blood sugar stability while also acting on appetite centers to reduce hunger. This Genopharm pack contains one vial holding 30 mg of Tirzepatide as a dry powder, together with a 2 ml ampoule of Sodium Chloride injection U.S.P. (0.9 % w/v) for reconstitution.

This dual mechanism gives Tirzepatide a stronger overall metabolic effect than single-pathway peptides, supporting gradual weight loss alongside improved glycemic control. The 30 mg vial is a multi-dose container: standard weekly doses run from 2.5 mg up to a maximum of 15 mg, so one vial covers several weeks of a titration schedule.

Najważniejsze korzyści

• Dual GIP/GLP-1 action for stronger glycemic and appetite control than single-receptor peptides
• Suppresses appetite and increases satiety, supporting gradual weight loss
• Stabilizes blood glucose both after meals and between meals
• Supports cardiovascular health markers relevant to metabolic patients
• Multi-dose 30 mg vial covers several weeks of a standard titration schedule
• Solvent ampoule included in the pack; produced under GMP (Good Manufacturing Practice)